A lung cancer trial found 21.1 months’ median survival with two drugs, versus 12.7 with one.
AstraZeneca's trial showed IMFINZI plus tarlatamab-dlle improved median survival to 21.1 months vs. 12.7 months with IMFINZI alone in extensive-stage small cell lung cancer. The combination reduced death risk by 58% and progression risk by 66%. Results were consistent across subgroups, including brain metastases. AstraZeneca aims to redefine treatment standards. Data presented at ESMO Congress 2026.
How this was made
The 30-second read
Why it matters
AstraZeneca's share price is expected to react positively on the day of the announcement, with potential upside in the weeks following as analysts update forecasts.
Market read
First‑report of pivotal trial data for a major oncology drug; likely to move AZN and related biotech stocks.
What to watch
The trial used a novel T‑cell engager; long‑term durability and regulatory pathway remain uncertain.
Background
The data were presented at the ESMO 2026 Congress and represent the first public disclosure of the DeLLphi‑305 trial results.
Ticker impact
AstraZeneca's IMFINZI plus tarlatamab‑dlle trial showed median OS 21.1 months vs 12.7 months for IMFINZI alone, a first‑report of pivotal Phase III data.
upside pressure as market prices in the survival benefit
Phase III data with statistically significant OS and PFS improvements are material for a large pharma; investors typically bid the stock on such breakthroughs.
Market effects
May boost the broader oncology/immune‑oncology sector as a new standard‑of‑care option.
Positive for US and European biotech equities, especially companies with checkpoint inhibitors.
High relevance for global pharma investors tracking immunotherapy pipelines.
Counterpoint
If safety concerns or later‑stage data reveal higher toxicity, the initial rally could reverse.
Key entities
- CompanyAstraZeneca
Pharmaceutical company developing IMFINZI (durvalumab).
- DrugIMFINZI
Durvalumab, an immunotherapy backbone in small‑cell lung cancer.
